Lo mejor del Congreso 2019 de la Sociedad Europea de Cardiología / The best of the 2019 European Society of Cardiology Congress / O melhor do Congresso da Sociedade Europeia de Cardiologia 2019

RESUMEN

Resumen El Congreso Europeo de Cardiología constituye uno de los eventos más relevantes de la comunidad cardiológica mundial. Fue realizado entre el 31 de agosto y el 4 de setiembre en el corazón de París, siendo el tema central la salud cardiovascular global. Como es habitual, contó con la presencia de más de 30.000 profesionales y destacados invitados. Se presentaron actualizaciones de varias guías de práctica clínica e importantes trabajos científicos que sin duda impactarán en el tratamiento de los pacientes con patología cardiovascular. A continuación realizaremos un breve resumen de algunos de los trabajos presentados - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes the ISAR-REACT 5 Trial

ABSTRACT

Summary: The European Congress of Cardiology is one of the most relevant events of the world cardiology community. It was held from August 31 to September 4 in the heart of Paris, France, the central theme being global cardiovascular health. As usual, it was attended by more than 30,000 professionals and prominent guests. Updates of several clinical practice guides and important scientific papers were presented. These undoubtedly will impact in the treatment of patients with cardiovascular pathology. Below we present a brief summary of some of the trials presented - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes the ISAR-REACT 5 Trial

RESUMO

Sumário O Congresso Europeu de Cardiologia é um dos eventos mais relevantes da comunidade mundial de cardiologia. Foi realizada de 31 de agosto ao 4 de setembro no coração de Paris, na França, o tema central foi a saúde cardiovascular global. Como sempre, participaram mais de 30.000 profissionais e convidados de destaque. Atualizações de vários guias de prática clínica e importantes artigos científicos foram apresentados que, sem dúvida, impactarão o tratamento de pacientes com patologia cardiovascular. Abaixo, faremos um breve resumo de alguns trials apresentados - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes the ISAR-REACT 5 Trial